These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32864605)

  • 1. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test
    Yang R; Huang B; A R; Li W; Wang W; Deng Y; Tan W
    Biosaf Health; 2020 Dec; 2(4):226-231. PubMed ID: 32864605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Neutralizing Antibodies in Serum Samples Using a SARS-CoV-2 Pseudotyped Virus Assay.
    Ferrero S; Batto MV; Gatto MI; Dimase F; Helguera G
    Curr Protoc; 2024 Oct; 4(10):e70025. PubMed ID: 39373132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
    Joseph J; Karthika T; Das VRA; Raj VS
    Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2.
    Hu J; Gao Q; He C; Huang A; Tang N; Wang K
    Genes Dis; 2020 Dec; 7(4):551-557. PubMed ID: 32837985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections.
    Yang R; Lan J; Huang B; A R; Lu M; Wang W; Wang W; Li W; Deng Y; Wong G; Tan W
    EBioMedicine; 2020 Aug; 58():102890. PubMed ID: 32707445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays.
    Manu AA; Owusu IA; Oyawoye FO; Languon S; Barikisu IA; Tawiah-Eshun S; Quaye O; Donkor KJ; Paemka L; Amegatcher GA; Denyoh PMD; Oduro-Mensah D; Awandare GA; Quashie PK
    Heliyon; 2024 May; 10(10):e31392. PubMed ID: 38826759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.
    Zhao G; Du L; Ma C; Li Y; Li L; Poon VK; Wang L; Yu F; Zheng BJ; Jiang S; Zhou Y
    Virol J; 2013 Aug; 10():266. PubMed ID: 23978242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms.
    Xu C; Wang A; Geng K; Honnen W; Wang X; Bruiners N; Singh S; Ferrara F; D'Angelo S; Bradbury ARM; Gennaro ML; Liu D; Pinter A; Chang TL
    Viruses; 2021 May; 13(6):. PubMed ID: 34064066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.
    Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays.
    Yu J; Li Z; He X; Gebre MS; Bondzie EA; Wan H; Jacob-Dolan C; Martinez DR; Nkolola JP; Baric RS; Barouch DH
    J Virol; 2021 May; 95(11):. PubMed ID: 33727331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
    Cai Z; Kalkeri R; Zhu M; Cloney-Clark S; Haner B; Wang M; Osman B; Dent D; Feng SL; Longacre Z; Glenn G; Plested JS
    Microorganisms; 2024 Feb; 12(3):. PubMed ID: 38543552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a SARS-CoV-2 neutralization assay based on a pseudotyped virus using a HIV system.
    Liang Z; Tong J; Wu X; Liu S; Wu J; Yu Y; Zhang L; Zhao C; Lu Q; Nie J; Huang W; Wang Y
    MedComm (2020); 2024 Apr; 5(4):e517. PubMed ID: 38525106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudotyped Viruses As a Molecular Tool to Monitor Humoral Immune Responses Against SARS-CoV-2 Via Neutralization Assay.
    Fantoni T; Bissoli M; Stefani C; Voi M; Dabija A; Casula R; Minafra DL; da Fonseca Palmeira J; Argañaraz ER; Mayora-Neto M; Temperton NJ; Zipeto D; Ruggiero A
    J Vis Exp; 2023 Nov; (201):. PubMed ID: 38078607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
    Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
    Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of pseudotyped VSV-SARS-CoV-2 spike variants for the assessment of neutralizing antibodies.
    Cimen AN; Torabfam GC; Tok YT; Yucebag E; Arslan N; Saribal D; Esken G; Dogan O; Kuskucu MA; Mete B; Aygun G; Tabak F; Can F; Ergonul O; Midilli K; Kutlu O; Cetinel S
    Bioanalysis; 2024; 16(21-22):1167-1177. PubMed ID: 39411978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.
    Bošnjak B; Stein SC; Willenzon S; Cordes AK; Puppe W; Bernhardt G; Ravens I; Ritter C; Schultze-Florey CR; Gödecke N; Martens J; Kleine-Weber H; Hoffmann M; Cossmann A; Yilmaz M; Pink I; Hoeper MM; Behrens GMN; Pöhlmann S; Blasczyk R; Schulz TF; Förster R
    Cell Mol Immunol; 2021 Apr; 18(4):936-944. PubMed ID: 33139905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An optimized and robust SARS-CoV-2 pseudovirus system for viral entry research.
    Yang P; Yang Y; Wu Y; Huang C; Ding Y; Wang X; Wang S
    J Virol Methods; 2021 Sep; 295():114221. PubMed ID: 34182038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.